Predictors of in-hospital mortality for patients admitted with ST-elevation myocardial infarction: a real-world study using the Myocardial Infarction National Audit Project (MINAP) database.
OBJECTIVE
Although early thrombolysis reduces the risk of death in STEMI patients, mortality remains high. We evaluated factors predicting inpatient mortality for patients with STEMI in a "real-world" population.


METHODS
Analysis of the Myocardial Infarction National Audit Project (MINAP) database using multivariate logistic regression and area under the receiver operating curve analysis.


METHODS
All acute hospitals in England and Wales.


METHODS
34 722 patients with STEMI from 1 January 2003 to 31 March 2005.


RESULTS
Inpatient mortality was 10.6%. The highest odds ratios for inpatient survival were aspirin therapy given acutely and out-of-hospital thrombolysis, independently associated with a mortality risk reduction of over half. A 10-year increase in age doubled inpatient mortality risk, whereas cerebrovascular disease increased it by 1.7. The risk model comprised 14 predictors of mortality, C index = 0.82 (95% CI 0.82 to 0.83, p<0.001). A simple model comprising age, systolic blood pressure (SBP) and heart rate (HR) offered a C index of 0.80 (0.79 to 0.80, p<0.001).


CONCLUSIONS
The strongest predictors of in-hospital survival for STEMI were aspirin therapy given acutely and out-of-hospital thrombolysis, Previous STEMI models have focused on age, SBP and HR We have confirmed the importance of these predictors in the discrimination of death after STEMI, but also demonstrated that other potentially modifiable variables impact upon the prediction of short-term mortality.
Gale
C P
CP
Division of Cardiovascular and Diabetic Research, Leeds Institute of Genetics Health and Therapeutics, University of Leeds, Leeds, UK. c.p.gale@leeds.ac.uk
Manda
S O M
SO
Batin
P D
PD
Weston
C F
CF
Birkhead
J S
JS
Hall
A S
AS
D000367:Age Factors; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000401:mortality* / Q000503:physiopathology; D001241:Aspirin / Q000627:therapeutic use; D001794:Blood Pressure / Q000502:physiology*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D017052:Hospital Mortality; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality*; D011379:Prognosis; D018570:Risk Assessment / Q000379:methods / Q000706:statistics & numerical data; D012737:Sex Factors; D016019:Survival Analysis; D015912:Thrombolytic Therapy / Q000379:methods* / Q000401:mortality; D013997:Time Factors; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D001241:Aspirin